Literature DB >> 25446726

Oesophageal cancer in 2014: Advances in curatively intended treatment.

Jesper Lagergren1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25446726     DOI: 10.1038/nrgastro.2014.213

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

Review 1.  Oesophageal cancer.

Authors:  Jesper Lagergren; Pernilla Lagergren
Journal:  BMJ       Date:  2010-11-26

2.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

3.  Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.

Authors:  Vera Oppedijk; Ate van der Gaast; Jan J B van Lanschot; Pieter van Hagen; Rob van Os; Caroline M van Rij; Maurice J van der Sangen; Jannet C Beukema; Heidi Rütten; Patty H Spruit; Janny G Reinders; Dick J Richel; Mark I van Berge Henegouwen; Maarten C C M Hulshof
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

4.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

5.  Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.

Authors:  Christophe Mariette; Laetitia Dahan; Françoise Mornex; Emilie Maillard; Pascal-Alexandre Thomas; Bernard Meunier; Valérie Boige; Denis Pezet; William B Robb; Valérie Le Brun-Ly; Jean-François Bosset; Jean-Yves Mabrut; Jean-Pierre Triboulet; Laurent Bedenne; Jean-François Seitz
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

6.  Safety of endoscopic mucosal resection for Barrett's esophagus.

Authors:  Yutaka Tomizawa; Prasad G Iyer; Louis M Wong Kee Song; Navtej S Buttar; Lori S Lutzke; Kenneth K Wang
Journal:  Am J Gastroenterol       Date:  2013-07-16       Impact factor: 10.864

7.  Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: the Rotterdam experience.

Authors:  E van Meerten; A van der Gaast; H W Tilanus; J W Poley; K Muller; H van Dekken
Journal:  J Surg Oncol       Date:  2009-07-01       Impact factor: 3.454

8.  Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer.

Authors:  Ryan P Merkow; Karl Y Bilimoria; Rajesh N Keswani; Jeanette Chung; Karen L Sherman; Lawrence M Knab; Mitchell C Posner; David J Bentrem
Journal:  J Natl Cancer Inst       Date:  2014-07-16       Impact factor: 13.506

9.  Radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

10.  Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial.

Authors:  K Nadine Phoa; Frederike G I van Vilsteren; Bas L A M Weusten; Raf Bisschops; Erik J Schoon; Krish Ragunath; Grant Fullarton; Massimiliano Di Pietro; Narayanasamy Ravi; Mike Visser; G Johan Offerhaus; Cees A Seldenrijk; Sybren L Meijer; Fiebo J W ten Kate; Jan G P Tijssen; Jacques J G H M Bergman
Journal:  JAMA       Date:  2014-03-26       Impact factor: 56.272

  10 in total
  8 in total

1.  miR-196a regulates the proliferation, invasion and migration of esophageal squamous carcinoma cells by targeting ANXA1.

Authors:  Changmei Hu; Jie Peng; Liang Lv; Xuehong Wang; Yuqian Zhou; Jirong Huo; Deliang Liu
Journal:  Oncol Lett       Date:  2019-03-22       Impact factor: 2.967

2.  MicroRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44.

Authors:  Jianhui Zuo; Kechao Zhu; Yunhai Wang; Zaicheng Yu
Journal:  Mol Cell Biochem       Date:  2017-11-01       Impact factor: 3.396

3.  MicroRNA-375 suppresses esophageal cancer cell growth and invasion by repressing metadherin expression.

Authors:  Changmei Hu; Liang Lv; Jie Peng; Deliang Liu; Xuehong Wang; Yuqian Zhou; Jirong Huo
Journal:  Oncol Lett       Date:  2017-04-26       Impact factor: 2.967

4.  PTENP1 inhibits the growth of esophageal squamous cell carcinoma by regulating SOCS6 expression and correlates with disease prognosis.

Authors:  Tuotuo Gong; Shuyu Zheng; Shan Huang; Shenbo Fu; Xuanwei Zhang; Shupei Pan; Tian Yang; Yuchen Sun; Ya Wang; Beina Hui; Jia Guo; Xiaozhi Zhang
Journal:  Mol Carcinog       Date:  2017-08-21       Impact factor: 4.784

5.  Identification of Differentially Expressed Genes and miRNAs Associated with Esophageal Squamous Cell Carcinoma by Integrated Analysis of Microarray Data.

Authors:  Lemeng Zhang; Jianhua Chen; Tianli Cheng; Hua Yang; Changqie Pan; Haitao Li
Journal:  Biomed Res Int       Date:  2020-07-01       Impact factor: 3.411

6.  MicroRNA-365 suppresses cell growth and invasion in esophageal squamous cell carcinoma by modulating phosphoserine aminotransferase 1.

Authors:  Changjiang Sun; Xizhi Zhang; Yong Chen; Qingqing Jia; Jianqi Yang; Yusheng Shu
Journal:  Cancer Manag Res       Date:  2018-10-15       Impact factor: 3.989

7.  IL-1RA suppresses esophageal cancer cell growth by blocking IL-1α.

Authors:  Sui Chen; Zhimin Shen; Zhun Liu; Lei Gao; Ziyang Han; Shaobin Yu; Mingqiang Kang
Journal:  J Clin Lab Anal       Date:  2019-05-17       Impact factor: 2.352

8.  miR‑378a‑3p exerts tumor suppressive function on the tumorigenesis of esophageal squamous cell carcinoma by targeting Rab10.

Authors:  Naixin Ding; Xiujin Sun; Tingting Wang; Lei Huang; Jing Wen; Yiqin Zhou
Journal:  Int J Mol Med       Date:  2018-04-24       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.